Intelligence · Clinical Pipeline

Infectious disease · Phase I

Infectious disease programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
240

Quick answer

Infectious disease Phase I programs: NovaPharmaNews indexes 240 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 5 of 5

  1. SOF/VEL/VOX

    Gilead Sciences Ireland UC

    HCV Infection

    phase 1 small molecule completed

    1 trial
  2. Safety Assessment of 10-Day Daily Bucco-Oral Administration of Transfer Factor in Healthy Adult Human Subjects

    s.r.o.

    healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections.

    phase 1 other active

    1 trial
  3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial
  4. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials
  5. Sotrovimab

    Vir Biotechnology

    COVID-19 Infection

    phase 1 mab terminated

    1 trial
  6. Sporozoite Challenge Model for Plasmodium vivax in Humans

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 mab completed

    1 trial
  7. Sulopenem

    Iterum Therapeutics plc

    Urinary Tract Infections

    phase 1 small molecule terminated

    1 trial
  8. TAF/EVG Vaginal Insert

    United Therapeutics Europe Ltd

    Hiv

    phase 1 small molecule completed

    1 trial
  9. TD-1607

    Theravance Biopharma Ireland Umited

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    phase 1 small molecule completed

    1 trial
  10. TD-1607

    Theravance Biopharma Ireland Umited

    Infections

    phase 1 small molecule completed

    1 trial
  11. TD-6450

    Theravance Biopharma Ireland Umited

    Hepatitis C

    phase 1 small molecule completed

    2 trials
  12. TI-0010

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 1 mab active

    1 trial
  13. TKM-100201

    Arbutus Biopharma Corp

    Ebola Virus Infection

    phase 1 small molecule terminated

    1 trial
  14. TKM-100802 for Injection

    Arbutus Biopharma Corp

    Ebola Virus Infection

    phase 1 small molecule terminated

    1 trial
  15. TNP-2092 capsules

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    phase 1 small molecule completed

    1 trial
  16. TVB-2640 - 50 mg

    Sagimet Biosciences

    Non-alcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial
  17. Telaprevir; Moxifloxacin; Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  18. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.

    Sciencepharma Sp. z o.o

    Not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial
  19. Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial

    Lacuna Pharma Pty Ltd

    Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection

    phase 1 other active

    1 trial
  20. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  21. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial
  22. UB-421 SC

    United Therapeutics Europe Ltd

    HIV-1-infection

    phase 1 mab active

    1 trial
  23. UB-421 SC(dB4C7C22-6 mAb)

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 1 mab completed

    1 trial
  24. UB-621

    United Therapeutics Europe Ltd

    Herpes Simplex Virus Infection

    phase 1 small molecule completed

    1 trial
  25. VCH 916

    Vertex Pharmaceuticals (Australia) Pty.

    HCV Infection

    phase 1 small molecule completed

    1 trial
  26. VCH-222

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  27. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Papillomavirus Infections

    phase 1 mab completed

    1 trial
  28. VGX-6150

    INOVIO PHARMACEUTICALS, INC.

    Hepatitis C, Chronic

    phase 1 mab completed

    1 trial
  29. VIR-1111

    Vir Biotechnology

    HIV I Infection

    phase 1 mab completed

    1 trial
  30. VIR-3434

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab completed

    1 trial
  31. VRON-0200-AdC6

    Vir Biotechnology

    Chronic Hepatitis B

    phase 1 mab active

    1 trial
  32. VX-985 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  33. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial
  34. Vebicorvir (VBR)

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial
  35. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial
  36. Woman-focused intervention

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 1 other completed

    1 trial
  37. XTL 6865

    XTL BIOPHARMACEUTICALS LTD

    Hepatitis C

    phase 1 small molecule active

    1 trial
  38. XTL-2125

    XTL BIOPHARMACEUTICALS LTD

    Chronic Hepatitis C Virus Infection

    phase 1 small molecule terminated

    1 trial
  39. Yinhu Qingwen Granules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Viral Pneumonia

    phase 1 small molecule active

    1 trial
  40. ZFN modified T cells

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 1 mab completed

    1 trial
  41. intraconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial
  42. randomized, double-blinded, placebo-controlled

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prevention of COVID-19 Caused by SARS-CoV-2

    phase 1 mab active

    1 trial
  43. routine HIV testing

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 other completed

    1 trial
  44. sD-NP-GT8 DNA

    INOVIO PHARMACEUTICALS, INC.

    HIV Infections

    phase 1 mab completed

    1 trial
  45. shenhuang granule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sepsis

    phase 1 small molecule active

    1 trial
  46. telaprevir formulation A

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  47. yimitasvir

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis c

    phase 1 small molecule completed

    1 trial
  48. zelicapavir (therapeutic dose)

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many infectious disease Phase I programs exist?

240 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs